Revvity, Inc. (RVTY)

Market Cap	12.70B
Revenue (ttm)	2.75B
Net Income (ttm)	693.09M
Shares Out	123.53M
EPS (ttm)	5.55
PE Ratio	18.54
Forward PE	21.71
Dividend	$0.28 (0.27%)
Ex-Dividend Date	Apr 18, 2024

Volume	168,666
Open	101.92
Previous Close	102.09
Day's Range	101.01 - 103.15
52-Week Range	79.50 - 132.54
Beta	1.09
Analysts	Buy
Price Target	118.91 (+15.66%)
Earnings Date	Apr 29, 2024

About RVTY

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its pro...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1937
• Employees: 11,500
• Stock Exchange: NYSE
• Ticker Symbol: RVTY

Financial Performance

In 2023, Revvity's revenue was $2.75 billion, a decrease of -16.95% compared to the previous year's $3.31 billion. Earnings were $693.09 million, an increase of 21.77%.

Analyst Forecast

According to 12 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price forecast is $118.91, which is an increase of 15.66% from the latest price.

Price Target

$118.91

(15.66% upside)

Analyst Consensus: Buy